307 related articles for article (PubMed ID: 18596031)
21. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
22. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
23. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
de Campos-Nebel M; Larripa I; González-Cid M
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824055
[TBL] [Abstract][Full Text] [Related]
25. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
[TBL] [Abstract][Full Text] [Related]
26. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
[TBL] [Abstract][Full Text] [Related]
27. Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.
Chen CF; He X; Arslan AD; Mo YY; Reinhold WC; Pommier Y; Beck WT
Mol Pharmacol; 2011 Apr; 79(4):735-41. PubMed ID: 21252292
[TBL] [Abstract][Full Text] [Related]
28. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
[TBL] [Abstract][Full Text] [Related]
29. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
30. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
[TBL] [Abstract][Full Text] [Related]
31. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
32. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.
Canela A; Maman Y; Huang SN; Wutz G; Tang W; Zagnoli-Vieira G; Callen E; Wong N; Day A; Peters JM; Caldecott KW; Pommier Y; Nussenzweig A
Mol Cell; 2019 Jul; 75(2):252-266.e8. PubMed ID: 31202577
[TBL] [Abstract][Full Text] [Related]
34. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
[TBL] [Abstract][Full Text] [Related]
35. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
[TBL] [Abstract][Full Text] [Related]
36. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Pourpak A; Landowski TH; Dorr RT
J Pharmacol Exp Ther; 2007 Jun; 321(3):1109-17. PubMed ID: 17351106
[TBL] [Abstract][Full Text] [Related]
37. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
38. NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells.
Wu SY; Pan SL; Xiao ZY; Hsu JL; Chen MC; Lee KH; Teng CM
PLoS One; 2014; 9(11):e112220. PubMed ID: 25372714
[TBL] [Abstract][Full Text] [Related]
39. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms.
Goodenow D; Emmanuel F; Berman C; Sahyouni M; Richardson C
Mutat Res Genet Toxicol Environ Mutagen; 2020 Jan; 849():503144. PubMed ID: 32087851
[TBL] [Abstract][Full Text] [Related]
40. The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation.
Zhao W; Jiang G; Bi C; Li Y; Liu J; Ye C; He H; Li L; Song D; Shao R
Oncotarget; 2015 Nov; 6(35):37871-94. PubMed ID: 26462155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
